Information  X 
Enter a valid email address

Synairgen PLC Ord 1P (SNG)

Related News

25-May-2022 12:00 PM

IN BRIEF: Synairgen shares fall as loss widens on higher costs

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Records a pretax loss of £57.9 million in 2021, widened from £17.7 million in 2020, as research and development costs jump to £52.9 million from £
16-May-2022 12:18 PM

IN BRIEF: Synairgen shares soar on positive analysis of SNG001

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Notes that it announced in February that its phase 3 Sprinter trial did not meet its primary endpoints of discharge from hospital and recovery. Says that the trial st
17-Mar-2022 11:48 AM

IN BRIEF: Synairgen falls as patient recruitment in US trial halted

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Says the US National Institute of Allergy & Infectious Diseases has halted all patient recruitment in its phase 2/3 Covid-19 trial. The trial included the assessm
21-Feb-2022 12:25 PM

Synairgen falls as trial for Covid treatment fails to meet endpoints

(Alliance News) - Synairgen PLC shares hit a 12-month low on Monday after the biotechnology company said that the late-stage trial of its Covid-19 treatment SNG001 did not meet primary or key secondary efficacy endpoints. Shares plunged
18-Dec-2020 09:49 AM

Synairgen fast-tracks trial of Covid-19 vaccine

Synairgen is speeding up its Phase III trial design evaluating SNG001 as a treatment for patients with Covid-19. Following discussions with the regulatory agencies it has made changes to its Phase III trial known as SG018. It has removed the lower dose
26-May-2020 07:10 AM

Synairgen posts annual loss; analysing potential Covid-19 treatment

Respiratory drug developer Synairgen posted a full-year loss, as it continued to spend on R&D, and said an investigation into a potential Covid-19 treatment was progressing well. Pre-tax losses for the year through December amounted to £4.8m, compa
25-Feb-2019 04:37 PM

Synairgen swings to loss on higher R&D spend

Respiratory drug developer Synairgen swung to an annual loss as it ramped up R&D spending. Pre-tax losses for the year through December amounted to £4.1m, compared to profits of £1.6m on-year. '2018 was a year of excellent operational p
25-Sep-2018 01:07 PM

Synairgen losses deepen on higher R&D spend

Respiratory drug company Synairgen posted a deeper first-half loss as it ramped up spending trialling a treatment for chronic obstructive pulmonary disease. Pre-tax losses for the six months through June amounted to £1.85m, widening from a loss of
22-Jun-2018 08:30 AM

Broker Forecast - finnCap issues a broker note on Synairgen PLC

finnCap today reaffirms its corporate investment rating on Synairgen PLC (LON:SNG) and raised its price target to 63p (from 35p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Mar-2018 09:21 AM

Synairgen swings to profit

Synairgen, the respiratory drug discovery and development company, swung to a profit from operations of £1.62 million in 2017, from a loss of £3.44 million the year before. Revenues for the year were £5.03 million (2016: £nil). R
07-Feb-2018 09:34 AM

Synairgen commences trail of obstructive pulmonary disease treatment

Synairgen said first patients had been dosed in a Phase II trial of an inhaled treatment for patients with chronic obstructive pulmonary disease. The first part of the trial of the treatment, referred to as SNG001, was scheduled to complete in the first
07-Feb-2018 08:20 AM

Broker Forecast - finnCap issues a broker note on Synairgen PLC

finnCap today reaffirms its corporate investment rating on Synairgen PLC (LON:SNG) and set its price target at 35p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
14-Dec-2017 09:59 AM

Synairgen revises collaboration with Pharmaxis

Synairgen, the respiratory drug discovery and development company, has revised its collaboration agreement with Pharmaxis following the completion of preclinical studies and the commencement of the Phase I clinical trial with its LOXL2 inhibitor programme
28-Jun-2017 01:01 PM

Synairgen shareholders pass all resolutions at AGM

Synairgen has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:01pm: (LON:SNG) Synairgen PLC share price was 0p at 8.75p Story provided by StockMarketWire.com...
16-Sep-2015 07:39 AM

Synairgen swings to H1 pretax loss

Synairgen has swung to an H1 pretax loss of £1.0m, from a prior same period profit of £1.9m. Revenue was £25,000, from £4.25m. CEO Richard Marsden commented: "During the period, Synairgen has been focused on working with AstraZeneca to support
21-Aug-2015 01:33 PM

Synairgen schedules interims

Synairgen will issue its interim results for the six month period to the end of June on 16 September. At 1:33pm: (LON:SNG) Synairgen PLC share price was 0p at 35.5p Story provided by StockMarketWire.com...
05-Aug-2015 07:33 AM

Synairgen announces research collaboration

Synairgen and Australian pharmaceutical company Pharmaxis Ltd have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). IPF
03-Mar-2015 09:21 AM

Synairgen swings to FY pretax profit

Synairgen has swung to a FY pretax profit of £1.13m, from a loss of £2.27m. Revenue was £4.3m, from nil. Chairman Simon Shaw said: "We are delighted with the progress Synairgen has made during what has been a transformational year with the lice
20-Mar-2014 08:15 AM

Synairgen FY pretax loss narrows slightly

Synairgen posted a FY pretax loss of £2.3m, from £2.5m a year earlier. Revenue was nil. Most of the loss was research and development expenditure, and other administrative expenses. Chairman Simon Shaw said Synairgen made significant progress this year
12-Aug-2013 07:36 AM

Synairgen narrows H1 pretax loss to £1.2m

Synairgen narrowed its first-half pretax loss to £1.19 million, from a loss of £1.26 million. It booked nil revenue. Total administrative expenses was £1.20 million, from £1.28 million. Chairman Simon Shaw said: "Significant progress has been
10-Jun-2013 01:54 PM

Synairgen resolutions passed at AGM

Synairgen has confirmed that all resolutions proposed at its annual general meeting held earlier today (10 June) were duly passed. At 1:54pm: (LON:SNG) Synairgen share price was 0p at 40p Story provided by StockMarketWire.com...
09-May-2013 01:09 PM

Synairgen schedules AGM

Synairgen - the respiratory drug discovery and development company - will hold its annual general meeting at the offices of Fasken Martineau, 17 Hanover Square, London W1S 1HU, on 10 June at noon. At 1:09pm: (LON:SNG) Synairgen share price was -2.25p a
13-Feb-2013 07:39 AM

Synairgen FY pretax loss £2.5m

Synairgen said in a trading update that its pretax loss for the six months to end-December 2012 was £2.5 million, from £2.2 million in the year-earlier same period. "In 2012 our interferon beta programme achieved a significant milestone, generatin
05-Dec-2012 07:57 AM

Synairgen in disucssions with potential licensing partners

Synairgen announced its interim results for the six months ended 30 June 2012. Since the interim period-end, the Company has made significant progress and has progressed discussions with potential licensing partners for SNG001 (inhaled interferon beta) fo
31-Aug-2012 07:55 AM

Synairgen presents proof of concept study

Synairgen has confirmed that Professor Ratko Djukanovic, Chief Investigator on Synairgen's recent Phase II study of inhaled interferon beta, will present "The effects of interferon beta on cold-induced asthma exacerbations" during the sessi

a d v e r t i s e m e n t